Effect of Atorvastatin on Serum Levels of Total Cholesterol and High-Sensitivity C-reactive Protein in High-Risk Patients with Atrial Fibrillation in Asia

Shi, Ming Yu; Xue, Feng; Teng, Shi Chao; Jiang, Li; Zhu, Jing; Yin, Feng; Gu, Hong

doi:10.1016/j.clinthera.2015.05.513

Cited by 4 publications

(3 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Today, non-toxic, biocompatible and biodegradable nanoparticles with various colloidal dimensions are being developed to enhance the penetration ability, reduce the frequency of doses, toxicity and to improve the therapeutic efficacy [18][19][20]. A number of clinical and experimental studies have demonstrated the effect of atorvastatin on atrial fibrillation, but the results are equivocal [21]. Due to technological innovations, today it is possible to enhance the bioavailability and improve the efficacy and safety of atrial fibrillation by developing the biodegradable combination of atorvastatin and curcumin-loaded chitosan nanoparticles for oral delivery.…”

Section: Introductionmentioning

confidence: 99%

Preparation and characterisation of atorvastatin and curcumin‐loaded chitosan nanoformulations for oral delivery in atherosclerosis

Kumara

Sistla

Madhusudhan

2017

IET nanobiotechnol.

View full text Add to dashboard Cite

Atorvastatin known to be a potential inhibitor of HMG-CoA reductase involved in the synthesis of cholesterol. It is touted as miracle drug due to its profound effect in decreasing the low-density lipoproteins in blood. Unfortunately, the high dosage used poses side-effects relatively in comparison to other statins. On the other hand, curcumin has a diverse therapeutic potential in health and disease. However, the poor aqueous solubility and low bioavailability hinders the therapeutic potential of it when administrated orally. Therefore, it was thought to minimise the frequency of atorvastatin doses to avoid the possibility of drug resistance and also to overcome the limitations of curcumin for desirable therapeutic effects by using nanocarriers in drug delivery. In this investigation, synergistic effect of atorvastatin and curcumin nanocarriers was encapsulated by chitosan polymer. The chitosan nanocarriers prepared by ionic gelation method were characterised for their particle size, zeta potential, and other parameters. The drug-loaded nanocarriers exhibited good encapsulation efficiency (74.25%) and showed a slow and sustained release of atorvastatin and curcumin 60.36 and 61.44%, respectively, in a span of 48 h. The drug-loaded nanocarriers found to be haemocompatible and qualified for drug delivery in atherosclerosis.

show abstract

Section: Introductionmentioning

confidence: 99%

Preparation and characterisation of atorvastatin and curcumin‐loaded chitosan nanoformulations for oral delivery in atherosclerosis

Kumara

Sistla

Madhusudhan

2017

IET nanobiotechnol.

View full text Add to dashboard Cite

show abstract

“…ATV was able to decrease LDL‐C and HS‐CRP in patients of European or South Asian origin . Most importantly, one study aimed at investigating the efficacy of ATV on levels of TC and HS‐CRP in atrial fibrillation (AF) patients in Asia suggested that ATV was significantly effective in lowering serum levels of HS‐CRP as well as TC so as to inhibit cardiovascular events . HS‐CRP, factor VII, and enhanced monocyte cytokine release were abnormalities, which could be attenuated by both ATV treatments .…”

Section: Discussionmentioning

confidence: 99%

High‐dose atorvastatin improves vascular endothelial function in patients with leukoaraiosis

Xue

Gong

et al. 2020

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Objective Leukoaraiosis (LA), as an age‐related white matter degeneration, is mainly caused by chronic ischemia. Our study aims to explore the efficacy of different doses of atorvastatin (ATV) in the vascular endothelial function in patients with LA. Methods Our study enrolled 402 LA patients who were then randomly included as control or treated with ATV (10 mg), ATV (20 mg), or ATV (30 mg). The total cholesterol (TC), triglycerides (TG), high‐density lipoprotein cholesterol (HDL‐C), and low‐density lipoprotein cholesterol (LDL‐C) were detected by enzyme colorimetric assay. The high‐sensitivity C‐reactive protein (hs‐CRP) level, reactive hyperemia index (RHI), endothelin‐1 (ET‐1) content, and nitric oxide (NO) level were tested by latex agglutination test, peripheral arterial tonometry technology, radioimmunoassay, and nitrate reductase assay, respectively. Results After 8 weeks of ATV treatment, the levels of TC, LDL‐C, and HS‐CRP decreased significantly, and the trends were demonstrated in a more significant way with the increases of dose of ATV. The treatment with ATV at different doses elevated NO level and RHI and declined ET‐1 content. Gastrointestinal reaction, muscular pain, and increased aminopherase were observed after treatment with the ATV at different doses with more obvious symptoms detected accompanied by the increase of the dose. The RHI was in negative correlation with the ET‐1 and HS‐CRP while in positive correlation with NO. Conclusion Our study demonstrates that ATV can significantly improve the vascular endothelial function in LA patients with a dose‐dependent effect.

show abstract

“…The mechanism for the occurrence of postoperative AF has been postulated to be associated with increased levels of systemic inflammatory markers and oxidative stress parameters preoperatively (Aviles et al, 2003). Several studies have indicated an association between AF and various inflammatory markers, such as high-sensitivity C-reactive protein (hs-CRP) and TC (Guo et al, 2012;Shi et al, 2015). Other studies have also suggested a role of preoperative arrhythmias as a predictor of POAF (Banach et al 2007).…”

Section: Statins In Postoperative Afmentioning

confidence: 99%

Statins and atrial fibrillation - mini - review on recent evidence

Sosnowska¹,

Banach²

2017

Heart Beat

View full text Add to dashboard Cite

show abstract

Effect of Atorvastatin on Serum Levels of Total Cholesterol and High-Sensitivity C-reactive Protein in High-Risk Patients with Atrial Fibrillation in Asia

Cited by 4 publications

References 33 publications

Preparation and characterisation of atorvastatin and curcumin‐loaded chitosan nanoformulations for oral delivery in atherosclerosis

Preparation and characterisation of atorvastatin and curcumin‐loaded chitosan nanoformulations for oral delivery in atherosclerosis

High‐dose atorvastatin improves vascular endothelial function in patients with leukoaraiosis

Statins and atrial fibrillation - mini - review on recent evidence

Contact Info

Product

Resources

About